论文部分内容阅读
肿瘤坏死因子相关的凋亡诱导配体(tumor necrosis factor related apoptosis-inducingligand,TRAIL)是肿瘤坏死因子超家族成员之一,由于它能特异性诱导肿瘤细胞的凋亡而对正常细胞无毒性,因此具有被开发成治疗肿瘤的蛋白质药物的可能性。目前已经有5个与TRAIL相关的受体被鉴定出,其中,TRAILR1和TRAILR2是与诱导细胞凋亡最直接相关的受体,也是最具有前景的药物设计靶点。本文基于TRAIL蛋白及其受体复合物的三维结构分析,阐述TRAIL诱导肿瘤细胞凋亡的机制以及影响凋亡的因素和途径,对以TRAIL为靶点的肿瘤治疗的研究现状作全面综述,为探索肿瘤生物治疗的新方法和途径提供帮助。
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a member of the tumor necrosis factor superfamily. Because it can specifically induce tumor cell apoptosis and is non-toxic to normal cells, Has the potential to be developed as a protein drug for the treatment of tumors. Five TRAIL-related receptors have been identified. Among them, TRAILR1 and TRAILR2 are the most directly related receptors for apoptosis induction and the most promising drug design targets. In this paper, based on the three-dimensional structure analysis of TRAIL protein and its receptor complex, we elucidated the mechanism of TRAIL-induced apoptosis and the factors and pathways that affect apoptosis. We reviewed the current status of TRAIL-targeted tumor therapy as Explore new ways and means of tumor biotherapy to help.